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OBJECTIVES: Hydroxychloroquine is an antimalarial agent that has been used in systemic lupus erythematosus
and rheumatoid arthritis treatment for many years. Recently, novel mechanisms of action have been proposed,
thereby broadening the therapeutic perspective of this medication. The purpose of this study was to evaluate
the immunomodulatory activity of hydroxychloroquine in T helper 17 (Th17) cytokines in healthy individuals
and patients.
METHODS: Eighteen female patients with systemic lupus erythematosus (mean age 39.0¡12.9 years) and 13
female patients with rheumatoid arthritis (mean age 51.5¡7.7 years) were recruited from Universidade Federal
de Pernambuco-Brazil. The patients were included after fulfilling four classification criteria for systemic lupus
erythematosus or rheumatoid arthritis from the American College of Rheumatology. After being stimulated
with phorbol 12-myristate 13-acetate and ionomycin in the absence or presence of different concentrations of
hydroxychloroquine, the interleukin 6, 17 and 22 levels were quantified with an enzyme-linked immunosorbent
assay in culture supernatants of peripheral blood mononuclear cells from healthy individuals and patients.
RESULTS: We demonstrated that in peripheral blood mononuclear cells from healthy volunteers and in systemic
lupus erythematosus and rheumatoid arthritis patients, there was a significant reduction in the IL-6, IL-17 and
IL-22 supernatant levels after adding hydroxychloroquine.
CONCLUSIONS Our in vitro results demonstrated that hydroxychloroquine inhibits IL-6, IL-17 and IL-22
production and contributes to a better understanding of the mechanism of action of this medication.
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& INTRODUCTION
Hydroxychloroquine (HCQ) is an antimalarial agent that
has been used in systemic lupus erythematosus (SLE) and
rheumatoid arthritis (RA) treatments for many years.
Recently, advances in our understanding of its mechanisms
of action have expanded the therapeutic prospects of HCQ
(1–3). Perhaps the most relevant discovery was of an
antagonistic effect of HCQ (inhibiting the immune response)
on Toll-like receptors (TLRs) (4). Other mechanisms, such as
interfering with antigen presentation and lysosomal acid-
ification, blocking UV light in cutaneous reactions and
inhibiting phospholipase A2, have been well described (5,6).
All of these molecular effects could partially explain the
immunomodulatory effect of HCQ upon proinflammatory
cytokines, such as IL-6, IL-1b and TNF-a (7).
Helper T cells (Th) are phenotypically heterogeneous and
classified according to the cytokines produced by the innate
immune system during the Th cell differentiation process.
Four main lineages, Th1, Th2, regulatory T cells (TReg) and
a novel cell named Th17, have been well described (8). The
activation and maturation of Th17 lymphocytes relies on
adequate T cell receptor (TCR) expression, co-stimulatory
molecules and cytokines. Combined, TGF-b, IL-1b, IL-6, IL-
21 and IL-23 play a pivotal role in properly differentiating
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naı¨ve CD4 positive cells. TGF-b and IL-6 are essential for
inducing transcription factors retinoic acid receptor-related
orphan receptor-t (RORct) and STAT-3 in naı¨ve CD4 positive
cells, which are responsible for promoting proper maturation.
IL-23 is another important cytokine that is required to expand
and stabilize the Th17 cell population (8).
Recently, Th17 cells have been implicated in SLE
pathogenesis, which identifies them as potential therapeutic
targets (9). Previous studies with SLE patients have
demonstrated an increase in serum Th17-related cytokines
(IL-17 and IL-23). Th17 appears to infiltrate targeted organs,
such as the kidneys and skin, which suggests an important
role of these cells in SLE pathogenesis (10–12). Moreover,
anti-DNAds and total IgG production in 15 lupus nephri-
tises were increased when the peripheral blood mono-
nuclear cells (PBMCs) were cultured with IL-17 (13). In RA,
activated T cells are a characteristic feature of synovial
inflammation, which suggests a Th1- and Th17-mediated
disease. Elevated levels of IL-17 have been observed in the
synovial fluid of these patients (14). Additionally, IL-17A-
producing CCR6+ memory T cells have been identified in
the synovial fluid of RA patients (15). These studies have
clearly shown that the Th17 pathway is implicated in the
pathogenesis of SLE and RA, but whether HCQ is able to
specifically down-regulate Th17 cytokines is unknown. To
our knowledge, our study is the first to address this issue.
& MATERIALS AND METHODS
Study Population
Eighteen female SLE patients (mean age 39.0¡12.9 years)
and 13 female RA patients (mean age 51.5¡7.7 years) were
recruited from the Rheumatology Division at the Hospital das
Clı´nicas-Universidade Federal de Pernambuco. All patients
answered a clinical questionnaire from which demographic,
clinical, current medication and laboratorial data were
collected (Table 1). Additional information was obtained from
hospital records and reviewed by experienced physicians. The
patients were included in the study after fulfilling at least four
or more of the classification criteria for SLE or RA (16,17) from
the American College of Rheumatology (ACR). After exclud-
ing any rheumatic disease, five healthy volunteers (mean age
25¡1.64 years) were recruited as the control group. Peripheral
blood samples were obtained from the patients and healthy
volunteers. Tests for serum anti-DNAds and serum comple-
ment (C3, C4 and CH50) were conducted using standard
methods.
PBMC purification
The PBMCs were obtained from the heparinized blood of
five healthy, non-smoking donors who had not taken any
drugs for at least 15 days prior to the sampling. The PBMCs
were isolated using the standard Ficoll-Hypaque
density-gradient centrifugation (GE Healthcare Biosciences,
Pittsburgh, PA, USA) method. The cells were counted in a
Neubauer chamber, and cell viability was determined using
the Trypan blue (Sigma-Aldrich, St. Louis, USA) exclusion
method. Cells were only used when their viability was.98%.
PBMC cultures
The PBMCs (1 6 106 cells/ml) were cultured in RPMI-
1640 (Gibco) supplemented with 10% fetal bovine serum
(Gibco, Carlsbad, CA, USA), HEPES 10 mM (Gibco,
Carlsbad, CA, USA) and penicillin (10.000 U/ml)/strepto-
mycin (10.000 mg/ml) (Gibco, Carlsbad, CA, USA). The cells
were stimulated with PMA (Sigma-Aldrich, St. Louis, USA)
+ Ionomycin (Sigma-Aldrich, St. Louis, USA) in the presence
or absence of HCQ (hydroxychloroquine sulfate, Sigma).
Methylprednisolone (Pfizer, New York, NY, USA) was used
as a positive control. The cells were incubated at 37 C˚ in a
humidified 5% CO2 incubator.
Cytokine titration
The cytokine levels in the culture supernatants were
determined using an enzyme-linked immunosorbent assay
(ELISA) kit according to the manufacturer’s instructions. In
culture, supernatants from PBMCs, IL-6 (BD Biosciences,
Franklinlakes, NJ, USA), IFN-c (BD Bioscience) and TNF-a
(BD Bioscience), levels were measured at 24 hours, and for
IL-17A (R&D Systems, Minneapolis, MN, USA), IL-22
(eBiosciences, San Diego, CA, USA), and IL-23p19,
(eBiosciences, San Diego, CA, USA) levels were measured
at 48 hours. The lower detection limits for the ELISA analyses
were as follows: 15.625 pg/ml for human IL-17 and human
TNF-a, 9.375 pg/ml for human IL-6 and IFN-c and 31.25 pg/
ml for human IL-23p19 and IL-22.
Statistical analysis
All results in this article were analyzed with univariate
comparisons using nonparametric tests (Wilcoxon matched-
pairs test) with p,0.01 considered a significant association
and p,0.05 a suggestive association. All quantitative data
were plotted with GraphPad Prism 3.02 software.
Ethics
All subjects signed informed consent forms that
were approved by the ethics committee of Universidade
Federal de Pernambuco in accordance with the Helsinki
Declaration.
& RESULTS
Effect of HCQ on the synthesis of cytokines of the
Th17 pathway in PBMCs of healthy volunteers
We investigated the effect HCQ on Th17 cytokines (IL-6,
IL-17 and IL-22) in the PBMCs of healthy volunteers. After
48 hours of stimulation with PMA and ionomycin, the HCQ
inhibited the production of IL-6, IL-17 and IL-22 (Figures 1
Table 1 - Demographic, clinical and current drug of the
patients with RA and SLE.
Diagnostic SLE RA
Number of patients 18 13
Age in years: mean ¡ SD
(range)
39¡12.9 (22–61) 51.5¡7.7 (40–69)
Disease duration in years:
mean (range)
10.9 (0.1–40) 8.1 (0.8–29.6)
Treatment N(%)
NSAIDS* – 1 (8%)
Steroids 12 (67%) 10 (77%)
Antimalarial agents 10 (55%) 3 (23%)
Methotrexate – 7 (53.8%)
Leflunomide – 4 (30.8%)
Azathioprine 4 (22%) –
Mycophenolate Mofetil 1 (5%) –
Thalidomide 1 (5%) –
*Non-steroidal anti-inflammatory drugs.
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A, B and C) in a dose-dependent manner. We did not
observe any significant inhibition in the production of these
cytokines using the Wilcoxon test (p.0.05). These results are
most likely caused by the small number of healthy
volunteers.
Effect of HCQ on the synthesis of Th17-related
cytokines in the PBMCs of SLE and RA patients
The main objective of this study was to evaluate the effect
of HCQ on the cytokine profile of SLE and RA patients.
Following our previous experiments in mice and healthy
individuals, we analyzed the effect of HCQ (at a concentra-
tion of 100 mM) on Th17 cytokine levels from the PBMCs of
SLE and RA patients after PMA and ionomycin stimulation.
The levels of IL-6, IL-17 and IL-22 were negligible in the
non-stimulated cells. There were remarkable increases in the
levels of these cytokines in the PBMCs from RA and SLE
patients, most likely because of the addition of PMA and
ionomycin.
Following HCQ administration in both the SLE and RA
patients, we found significant inhibition in the levels of IL-6
(p= 0.0001 for SLE and p= 0.0025 for RA, Figures 2A and
Figure 1 - Inhibition of IL-17A (A), IL-22 (B) and IL-6 (C)
supernatants levels in PBMCs from five healthy individuals using
HCQ at 25 mM, 50 mM and 100 mM doses.
Figure 2 - Inhibition of IL-6 (A), IL-17 (B) and IL-22 (C) production
using HCQ at a dose of 100 mM in PBMCs from SLE patients.
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3A), IL-17 (p= 0.0001 for SLE and p= 0.0002 for RA,
Figures 2B and 3B) and IL-22 (p= 0.0067 for SLE and
p = 0.0002 for RA, Figures 2C and 3C).
& DISCUSSION
In the present study, we found that the antimalarial
medication HCQ decreased pro-inflammatory Th17 cyto-
kines levels in the PBMCs from healthy individuals and
SLE/RA patients, suggesting a novel mechanism of action
for these antirheumatic drugs. To our knowledge, this study
is the first report of an inhibitory effect of antimalarial
medication on IL-17 and IL-22 supernatant levels.
Increasingly, experimental and clinical evidence has
indicated that IL-17 and Th17 cells play a central role in
SLE and RA pathogenesis (10,18). IL-17 amplifies the
immune response by increasing target organ inflammation
and damage and by augmenting antibody production by B
cells, an important player in SLE (19). In RA patients, the IL-
17 serum and synovial levels are positively correlated with
disease activity and upregulate osteoclast activation, which
promotes bone erosion (20). Recently, our group described
the upregulation of serum IL-22 levels in RA patients and
identified an important correlation with disease activity and
the presence of erosion (21).
Antimalarials have been widely used to treat SLE patients
for many years, particularly for cutaneous and musculoske-
letal manifestations (22,23). HCQ should also be used as a
maintenance treatment in patients with stable disease, as
previously reported in a randomized controlled trial in
which the placebo group presented more lupus flares than
the HCQ group (24,25). These results suggest that an
immunomodulatory ‘status’ is induced by HCQ, which
could contribute to adequate disease control over many
years. Another important beneficial effect of HCQ is a well-
demonstrated reduction in cardiovascular risk in SLE
patients. Previous cohort studies have shown a significant
reduction in cholesterol levels, carotid plaque formation and
thrombosis frequency (26,27). Recently, antimalarials have
also improved survival in different populations of SLE
patients (28,29).
For RA treatment, controlled trials have demonstrated
the efficacy of HCQ in controlling arthritis symptoms as
antimalarial agents are classified as disease-modifying
antirheumatic drugs (DMARD) (30). Compared with other
antirheumatic drugs, DMARDs are relatively well tolerated
and safe to use during pregnancy and lactation.
Additionally, these medications could improve glycemic
control and lipid profiles, thereby decreasing cardiovascular
risks in RA patients. An observational study described a
38% risk reduction of developing diabetes in RA patients
after a long follow-up period (31).
In the present study, HCQ exhibited an anti-inflammatory
effect on Th17-related cytokines in healthy individuals and
SLE and RA patients. Previous studies using different cell
populations have demonstrated that HCQ inhibits proin-
flammatory cytokines, such as tumor necrosis factor-alpha
(TNF-alpha), interferon-gamma (IFN-gamma), IL-1-alpha
and IL-6 (32,33). These results are in accordance with our
findings, but few studies have evaluated the in vitro effect of
HCQ upon supernatant levels of T-cell related cytokines.
An interesting issue regarding our study is whether ‘in
vivo’ treatment using antimalarial agents could influence the
in vitro HCQ effect. In our sample, although only a minority
of patients was currently using HCQ, we found no
differences when comparing patients with or without
HCQ treatment (data not shown). In fact, in our study
design, we compared the cytokine supernatant levels before
and after administering HCQ to the same patient. Thus,
each patient was his or her own control, and ‘in vivo’ HCQ
use was not a confounding variable.
The exact mechanism by which HCQ reduces IL-6, IL-17
and IL 22 levels is unknown, but one possible explanation is
that it occurs by reducing Th17 cells through a decrease in
the antigen presentation. Antimalarials classically enter
lysosomes, causing an increase in cell pH, which interferes
with protein processing and secretion (6). Moreover, the
Figure 3 - Inhibition of IL-6 (A), IL-17 (B) and IL-22 production (C)
using HCQ at a dose of 100 mM in PBMCs from RA patients.
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inhibitory effect of HCQ on TLR expression decreases the
aberrant immune response typically found in rheumatic
diseases. In fact, there is growing evidence that TLRs,
particularly TLR 9, play pivotal roles in SLE and RA (34,35).
One limitation of our study was the inability to identify
the Th17 cells through a specific technique, such as flow
cytometry. However, we identified a consistent inhibitory
effect in mice, healthy individuals and patients, suggesting a
significant inhibitory effect upon cytokines involved in Th17
activation. Regarding IL-6, our results are in accordance
with a previous study of 14 SLE patients, which showed a
decrease in IL-6 mRNA expression in skin samples after
three months of chloroquine treatment (7).
Although different mechanisms of action have been
previously described, it has not been established whether
HCQ is able to suppress the cytokines produced by Th17
cells. Our in vitro results demonstrated that this medication
can inhibit IL-6, IL-17 and IL-22 production, which may be a
novel pathway to understanding the immunomodulatory
properties of HCQ.
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